-
EZ Cap™ Human PTEN mRNA: Workflow & Applications
2026-09-20
Build reproducible PTEN restoration assays with Cap 1, poly(A)-tailed mRNA for transient expression, pathway analysis, and delivery-system development. The workflow also shows how the same tumor suppressor gene mRNA can progress from routine cell transfection to HA-LNP studies in melanoma models.
-
H2S Persulfidation and Ferroptosis in NSCLC
2026-09-19
A 2024 Molecular Cell study identifies hydrogen sulfide-mediated persulfidation of S-adenosylhomocysteine hydrolase as a metabolic mechanism that sensitizes non-small cell lung cancer cells to ferroptosis. The work connects impaired homocysteine metabolism with reduced cysteine and glutathione availability under cystine-depletion conditions, providing a mechanistic rationale for combining hydrogen sulfide signaling with ferroptosis-based treatment strategies.
-
Methylprednisolone Sodium Succinate: Research Guide
2026-09-18
Methylprednisolone Sodium Succinate is a synthetic corticosteroid used in inflammation, immunology, and apoptosis research. Its glucocorticoid-receptor activity can suppress proinflammatory gene programs, but concentration-dependent leukocyte effects and limited clinical evidence require careful model selection.
-
Ertapenem Sodium Salt in Resistance Research
2026-09-18
Use Ertapenem sodium salt to build reproducible susceptibility, time-kill, and resistance-surveillance workflows rather than treating it as a single endpoint reagent. Its broad-spectrum benchmark value pairs naturally with plasmid localization and transfer assays for investigating carbapenem-resistant Enterobacter cloacae.
-
Human iPSC Intestinal Organoids for PK Studies
2026-09-17
Saito and colleagues established a direct three-dimensional culture workflow for generating expandable intestinal organoids from human induced pluripotent stem cells. The resulting organoids can be propagated, cryopreserved, and converted into two-dimensional intestinal epithelial cultures with enterocyte-associated metabolic and transporter activities, offering a more human-relevant platform for oral drug pharmacokinetic studies.
-
MG-132 for Reliable Cell Death Assays
2026-09-17
This scenario-driven guide explains how MG-132 (SKU A2585) can improve experimental planning for viability, apoptosis, cell-cycle, and oxidative-stress assays. It connects formulation, storage, dose selection, and ferroptosis-related interpretation to practical laboratory decisions.
-
BRCAness and Olaparib Sensitivity in Mesothelioma
2026-09-16
Borchert et al. combined drug-response experiments with homologous recombination repair gene-expression profiling to investigate why malignant pleural mesothelioma may respond to PARP inhibition. Their data link BAP1-associated BRCAness with enhanced olaparib activity, particularly alongside cisplatin, while identifying a clinically relevant expression pattern and candidate prognostic markers.
-
Chlorpromazine: A Rigorous Assay Design Guide
2026-09-16
Chlorpromazine can serve as more than a dopamine-pathway probe: it can help researchers design and interpret pharmacological assays across neurobiology and nanomedicine. This guide connects chlorpromazine hydrochloride research with cell-specific nanoparticle uptake findings while emphasizing controls, assay boundaries, and reproducibility.
-
Aminopeptidase Selectivity of ACE Inhibitors
2026-09-15
This 1992 study re-evaluated how bestatin and several metallopeptidase inhibitors affect aminopeptidases N, A, and W. Its central contribution was to distinguish broad aminopeptidase inhibition from comparatively selective ACE-inhibitor activity, while identifying sulfhydryl ACE inhibitors as a possible source of AP-W-related off-target effects.
-
From Reporter Signal to Translational Confidence
2026-09-15
A thought-leadership framework for using Firefly Luciferase mRNA as a mechanistically informed control in delivery studies, from assay validation to regenerative-medicine translation.
-
Peptidisc-Assisted Nanobody Clustering: Study Insights
2026-09-14
The reference preprint introduces peptidisc-assisted hydrophobic clustering as a way to assemble nanobodies into soluble multimeric, bispecific, and autofluorescent proteins. Its results suggest that membrane-mimetic stabilization can translate nanobody multivalency into stronger apparent binding while avoiding conventional tandem-linker or scaffold-fusion designs.
-
Forskolin and the Next Generation of Organoid Models
2026-09-14
Forskolin is more than a routine cAMP reagent: as a direct adenylate cyclase activator, it can become a controllable perturbation for organoid engineering, stem-cell validation, and translational disease modeling. This article connects its mechanism with pancreatic ductal organoid research while defining practical safeguards for moving from pathway activity to meaningful biological insight.
-
Angiotensin I Workflow for ACE Assays
2026-09-13
Use Angiotensin I as a defined substrate to separate renin–angiotensin system activity from downstream receptor effects. This practical workflow combines ACE-conversion controls, peptide-handling guidance, spectral quality lessons, and applications in cardiovascular disease mechanisms, antihypertensive drug screening, and neuroendocrine models.
-
Bufuralol Hydrochloride in Human Organoid PK
2026-09-12
Bufuralol hydrochloride is a non-selective β-adrenergic receptor antagonist whose partial agonist behavior makes exposure and model context central to interpretation. This article connects its cardiovascular pharmacology with human iPSC-derived intestinal organoids to develop a more rigorous framework for pharmacokinetic and β-adrenergic modulation studies.
-
Clarithromycin CYP3A Inhibition: Bench Workflow
2026-09-11
Use Clarithromycin as a controlled CYP3A inhibitor challenge for drug-drug interaction research, statin metabolism interaction assays, and translational pharmacokinetic studies. This workflow emphasizes solvent control, matrix selection, orthogonal controls, and the important contrast between CYP3A-dependent metabolism and dabigatran pathways that do not rely on cytochrome P450.